

Philippe O Gannon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8742909/publications.pdf>

Version: 2024-02-01

14
papers

712
citations

1040056

9
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

1418
citing authors

#	ARTICLE	IF	CITATIONS
1	Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allosteric regulating HLA specificity. <i>PLoS Computational Biology</i> , 2017, 13, e1005725.	3.2	250
2	Long-lasting stem cell-like memory CD8 ⁺ T cells with a naïve-like profile upon yellow fever vaccination. <i>Science Translational Medicine</i> , 2015, 7, 282ra48.	12.4	174
3	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	4.8	73
4	Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3285-3296.	7.0	47
5	Lymphatic vessel density is associated with CD8 ⁺ T cell infiltration and immunosuppressive factors in human melanoma. <i>Oncolmmunology</i> , 2018, 7, e1462878.	4.6	47
6	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 391.	4.4	42
7	Quantitative TCR:pMHC Dissociation Rate Assessment by NTAMers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence. <i>Journal of Immunology</i> , 2015, 195, 356-366.	0.8	30
8	Epitope located N-glycans impair the MHC-I epitope generation and presentation. <i>Electrophoresis</i> , 2016, 37, 1448-1460.	2.4	14
9	Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine. <i>Vaccines</i> , 2020, 8, 25.	4.4	13
10	Heterogeneity assessment of functional T cell avidity. <i>Scientific Reports</i> , 2017, 7, 44320.	3.3	10
11	Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. <i>Cytotherapy</i> , 2020, 22, 780-791.	0.7	9
12	Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
13	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2533-2533.	1.6	0
14	TCR-Ligand Dissociation-Rate, a Reliable and Determining Parameter, Identifying Tumor-Reactive CD8 T Cells of High Avidity and Functional Potency. <i>Blood</i> , 2016, 128, 5894-5894.	1.4	0